FOR IMMEDIATE RELEASE
CONTACT: ERIC WOOLSON
FRIDAY, NOVEMBER 20, 2009
515-681-3967

EXEMPLAR GENETICS TEAM PARTICIPATES IN AALAS
60th ANNUAL NATIONAL MEETING IN DENVER NOV. 8-12

The Exemplar Genetics leadership team has returned from attending the 60th annual national meeting of the American Association for Laboratory Animal Science in Denver, Colorado.

The AALAS conference is an outstanding source for regulatory training and provides workshops on a number of other critically important topics,” said Troy Arends, director of business development.  “It’s also the perfect setting for us to meet with existing clients, potential clients and the scientists who work in the research field. Our goal is to establish and maintain long-term working relationships and our presence at the annual AALAS meetings is part of that ongoing process of staying connected.”

The American Association for Laboratory Animal Science is a nonprofit membership association that is the premier forum for the exchange of information and expertise in the care and use of laboratory animals. Since 1950, the organization has been dedicated to the humane care and treatment of laboratory animals and the quality research that leads to scientific gains that benefit people and animals.

Brian Dacken, Exemplar Genetics’ manager of clinical research, met with Food and Drug Administration officials and continued to stay abreast of ever-changing federal guidelines and industry best management practices through one of the meeting workshops, Keeping Current with Regulations and Requirements.

Arends noted that the management team focused its promotional activities at last year’s meeting on its Lonestar Swine operations, which produce Miniature Yucatan pigs for the research field.

“This year, we continued to share the Lonestar Laboratory Swine story but we also communicated the advances we’ve made at Exemplar Genetics.  Specifically the licensing and availability of genetically engineered CFTR animals,” Arends said. “Working with the University of Iowa, we have achieved ground-breaking results that have put us at the top of our industry.  We continue to get the message out that the technology we licensed can enable discovery and ultimately help researchers find therapies and cures that will change people’s lives.”